How does the continued emergence of new drugs impact the use of stem cell transplant for myeloma patients? Dr. Gareth Morgan, a leading researcher at The Royal Marsden in the United Kingdom, suggests that the standard therapies available today will continue to offer good results for standard-risk patients. Dr. Morgan also argues that research should focus instead on the “20 to 30 percent” of multiple myeloma patients living with high-risk disease.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…